Van Hulzen Asset Management LLC Invests $476,000 in Prestige Consumer Healthcare Inc. $PBH

Van Hulzen Asset Management LLC acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 10,077 shares of the company’s stock, valued at approximately $476,000.

Other institutional investors have also made changes to their positions in the company. AQR Capital Management LLC increased its stake in Prestige Consumer Healthcare by 11.9% in the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock valued at $2,558,000 after buying an additional 3,200 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Prestige Consumer Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock worth $2,535,000 after buying an additional 1,289 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Prestige Consumer Healthcare by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after acquiring an additional 120,965 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Prestige Consumer Healthcare by 204.0% in the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock valued at $9,010,000 after acquiring an additional 70,330 shares in the last quarter. Finally, Geneos Wealth Management Inc. increased its position in shares of Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after acquiring an additional 269 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Down 1.2%

Shares of Prestige Consumer Healthcare stock opened at $51.38 on Wednesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. The business has a fifty day simple moving average of $49.90 and a two-hundred day simple moving average of $54.84. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $71.07. The company has a market capitalization of $2.43 billion, a price-to-earnings ratio of 14.39, a P/E/G ratio of 1.63 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.09. The company had revenue of $265.71 million for the quarter, compared to analyst estimates of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The company’s revenue was up 6.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, August 10th. Canaccord Genuity Group cut their price objective on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Finally, Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).